Prognostic Impact of Tumor Budding on Moroccan Colon Cancer Patients.
Journal
International journal of surgical oncology
ISSN: 2090-1410
Titre abrégé: Int J Surg Oncol
Pays: United States
ID NLM: 101566285
Informations de publication
Date de publication:
2022
2022
Historique:
received:
10
11
2021
accepted:
05
01
2022
entrez:
31
1
2022
pubmed:
1
2
2022
medline:
2
2
2022
Statut:
epublish
Résumé
Tumor budding is now emerging as one of the robust and promising histological factors that play an important role in colon cancer. In this study, we aimed to investigate the association between tumor budding and tumor clinicopathological factors, tumor molecular signature, and patient survival for the first time in a Moroccan population. We collected data of 100 patients operated from colon adenocarcinoma. Tumor budding was assessed on HES slides, according to the International Tumor Budding Consensus Conference 2016 recommendations. The expression of MMR proteins was performed by immunohistochemistry. KRAS and NRAS mutations testing was performed by Sanger sequencing and pyrosequencing. High tumor budding grade (BUD 3) was found to be significantly associated with adverse clinicopathological features including older age ( Based on these findings and the ITBCC group recommendations, tumor budding should be taken into account along with other clinicopathologic factors in the risk assessment of colorectal cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Tumor budding is now emerging as one of the robust and promising histological factors that play an important role in colon cancer. In this study, we aimed to investigate the association between tumor budding and tumor clinicopathological factors, tumor molecular signature, and patient survival for the first time in a Moroccan population.
METHODS
METHODS
We collected data of 100 patients operated from colon adenocarcinoma. Tumor budding was assessed on HES slides, according to the International Tumor Budding Consensus Conference 2016 recommendations. The expression of MMR proteins was performed by immunohistochemistry. KRAS and NRAS mutations testing was performed by Sanger sequencing and pyrosequencing.
RESULTS
RESULTS
High tumor budding grade (BUD 3) was found to be significantly associated with adverse clinicopathological features including older age (
CONCLUSIONS
CONCLUSIONS
Based on these findings and the ITBCC group recommendations, tumor budding should be taken into account along with other clinicopathologic factors in the risk assessment of colorectal cancer.
Identifiants
pubmed: 35096426
doi: 10.1155/2022/9334570
pmc: PMC8799359
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9334570Informations de copyright
Copyright © 2022 Fatima El Agy et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Nat Rev Clin Oncol. 2021 Feb;18(2):101-115
pubmed: 32901132
Br J Cancer. 2016 Jul 12;115(2):156-63
pubmed: 27299960
Nat Rev Cancer. 2018 Apr;18(4):203-204
pubmed: 29376521
J Clin Med. 2016 Apr 29;5(5):
pubmed: 27136592
Pathology. 2015 Oct;47(6):551-6
pubmed: 26352110
Hum Pathol. 2017 Jul;65:21-30
pubmed: 28188750
J Surg Oncol. 2003 May;83(1):42-7
pubmed: 12722096
Br J Cancer. 2016 Sep 27;115(7):831-40
pubmed: 27599041
Ann Surg Oncol. 2018 Jan;25(1):204-211
pubmed: 29086140
Br J Cancer. 2018 Nov;119(10):1244-1251
pubmed: 30385823
Dis Colon Rectum. 2003 Aug;46(8):1054-9
pubmed: 12907899
Dis Colon Rectum. 2008 May;51(5):568-72
pubmed: 18286339
PLoS One. 2021 Mar 30;16(3):e0248522
pubmed: 33784337
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Hum Pathol. 2007 Nov;38(11):1696-702
pubmed: 17707462
Hum Pathol. 2016 Jan;47(1):4-19
pubmed: 26476568
Am J Surg Pathol. 2015 Oct;39(10):1340-6
pubmed: 26200097
J Clin Pathol. 2003 Jan;56(1):69-73
pubmed: 12499439
BMC Cancer. 2015 Jan 21;15:14
pubmed: 25603809
JNCI Cancer Spectr. 2020 Oct 16;5(1):pkaa093
pubmed: 33554032
Virchows Arch. 2017 Mar;470(3):341-346
pubmed: 28130698
Mod Pathol. 2017 Sep;30(9):1299-1311
pubmed: 28548122
Hum Pathol. 2017 Jul;65:62-70
pubmed: 28438617
J Clin Med. 2020 Sep 03;9(9):
pubmed: 32899322
Anticancer Res. 2018 Aug;38(8):4713-4721
pubmed: 30061240
Histopathology. 2012 Nov;61(5):777-87
pubmed: 22803799
Hum Pathol. 2019 Mar;85:145-151
pubmed: 30428391
J Gastrointest Cancer. 2015 Sep;46(3):212-8
pubmed: 25994502
Asian Pac J Cancer Prev. 2018 Sep 26;19(9):2447-2453
pubmed: 30255698
Br J Cancer. 2012 May 22;106(11):1713-7
pubmed: 22531633
Dis Markers. 2019 Dec 7;2019:3210710
pubmed: 31885734
Cancer Treat Rev. 2015 Feb;41(2):151-9
pubmed: 25549950